Utilization of P2Y₁₂ Inhibitors in Older Adults With ST-Elevation Myocardial Infarction and Frailty.

ABSTRACT: Choosing optimal P2Y₁₂ inhibitor in frail older adults is challenging because they are at increased risk of both ischemic and bleeding events. We conducted a retrospective cohort study of Medicare Advantage Plan beneficiaries who were prescribed clopidogrel, prasugrel, or ticagrelor after percutaneous coronary intervention-treated ST-elevation myocardial infarction from January 1, 2010 to December 31, 2020. Frailty was defined using claims-based frailty index ≥0.25. We conducted multivariable logistic regression to identify factors associated with using potent P2Y₁₂ inhibitors and multivariable-adjusted competing risk analyses to compare the rate of discontinuation of potent P2Y₁₂ inhibitors in frail versus non-frail patients. There were 11,239 patients (me

SUBMITTER: Ko D 

PROVIDER: S-EPMC10840744 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature